Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis

摘要

BackgroundHepatocellular carcinoma (HCC) is one of the deadliest malignancies worldwide due to the lack of effective treatments. Chemoprevention in high-risk patients is a promising, alternative strategy. In this study, pioglitazone was investigated for its ability to prevent hepatocarcinogenesis in two rodent models of cirrhosis.